Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.
Ovarian Cancer|Fallopian Cancer|Peritoneal Cancer
DRUG: ENMD-2076
Progression free survival rate, 6 months
The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.